Fluorine As Only Halogen Patents (Class 514/759)
  • Patent number: 9012474
    Abstract: The invention relates to pharmaceutical compositions comprising (i) a fluoroquinolone, (ii) a salt formed between a carboxylate anion and a divalent metal cation, (iii) a liquid comprising an organic solvent selected from the group consisting of glycerol, propylene glycol, glycerol formal, and (iv) optionally water. The invention further relates to methods of treating or preventing a condition in an animal comprising administering to the animal in need thereof a pharmaceutical composition of the invention.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: April 21, 2015
    Assignee: Idexx Laboratories Inc.
    Inventor: Yerramilli V. S. N. Murthy
  • Patent number: 8986738
    Abstract: A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: March 24, 2015
    Assignee: NOVALIQ GmbH
    Inventor: Hasso Meinert
  • Patent number: 8961873
    Abstract: The present invention describes a new system and method, named “Antinfection”, to protect primarily healthcare workers (HCWs) and patients against communicable and nosocomial infections. It's based on new antiseptic sprays, non-alcoholic, that can be sprayed automatically on the hands. The base of the antiseptic action is the persistent part, preventing the colonization of tissue and non-living surfaces with microorganisms through the targeted, on-demand release of Fluorine ions. The system including new sprayers for fast and controlled application; new technologies to secure the long-term protection against wear in the daily work routines of HCWs; new measurement techniques for the quality of the Antinfection; new quality recording concepts for the promotion and verification of new strategies and campaigns in the “lost war against the germs”.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: February 24, 2015
    Inventors: Fridolin Voegeli, Ghanem E. Ghanem
  • Publication number: 20140371329
    Abstract: An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: Evan C. Unger, Ed Marinelli
  • Patent number: 8822549
    Abstract: An oxygen therapeutic composition, comprising a perfluorocarbon material, a viscosity modifier, a buffer, wherein the buffer stabilizes a pH of the composition at between about 6.5 to about 7.5, and wherein the composition comprises a viscosity of about 2.0 to about 3.5 mPas, and wherein the fluorocarbon has a boiling point of about 4 degrees Celsius to about 60 degrees Celsius.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: September 2, 2014
    Inventors: Jennifer L. Johnson, Evan C. Unger
  • Patent number: 8748497
    Abstract: The present invention is directed to a stable fluorocarbon emulsion having a continuous aqueous phase and discontinuous fluorocarbon phase comprising two fluorocarbons and surprisingly demonstrates that perfluorodecyl bromide is as effective in stabilizing perfluorooctyl bromide emulsions of certain concentrations than much more highly concentrated perfluorooctyl bromide/perfluorodecyl bromide emulsions without the significant problems experienced in higher concentrated emulsions such as longer organ retention times, formation of PFDB crystals, larger emulsion particles, manufacturing problems and inability of repeat dosing inherent with higher concentrations of perfluorodecyl bromide.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: June 10, 2014
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jeffry Weers, David Klein, Cindy Johnson
  • Publication number: 20140004099
    Abstract: The present invention provides methods and combinations for reducing the infarct volume in a tissue of a subject undergoing ischemia or at risk of developing ischemia.
    Type: Application
    Filed: September 4, 2013
    Publication date: January 2, 2014
    Inventors: William Culp, Robert Skinner, Evan Unger
  • Patent number: 8513309
    Abstract: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: August 20, 2013
    Assignee: Oxygen Biotherapeutics, Inc.
    Inventor: Gerald Klein
  • Publication number: 20130165839
    Abstract: A treatment system and method includes use of a chemical facilitator to provide a result-effective event against one or more negative therapeutic effects related to exposing to a light output a skin portion including a condition treatable in whole or in part with light. In one exemplary embodiment for skin treatment including tattoo removal, perfluorodecalin is used to inhibit or resolve whitening, for example to speed a laser therapy session.
    Type: Application
    Filed: January 30, 2013
    Publication date: June 27, 2013
    Inventor: Michael P. O'Neil
  • Publication number: 20130129635
    Abstract: The present invention relates to the fabrication and use of microbubbles. In some embodiments, the invention provides for the fabrication and use of polymerized shell lipid microbubbles (PSMs). The microbubbles of the invention can be used, for example, for diagnosis and treatment of a condition.
    Type: Application
    Filed: May 24, 2011
    Publication date: May 23, 2013
    Applicant: Wilson Sonsini Goodrch & Rosati
    Inventors: Jon Nagy, Joyce Wong, Adam Luce, Ragnhild Whitaker, Robin Cleveland, Yoonjee Park
  • Publication number: 20130096204
    Abstract: An oxygen therapeutic composition, comprising a perfluorocarbon material, a viscosity modifier, a buffer, wherein the buffer stabilizes a pH of the composition at between about 6.5 to about 7.5, and wherein the composition comprises a viscosity of about 2.0 to about 3.5 mPas, and wherein the fluorocarbon has a boiling point of about 4 degrees Celsius to about 60 degrees Celsius.
    Type: Application
    Filed: October 13, 2011
    Publication date: April 18, 2013
    Inventors: Jennifer L. Johnson, Evan C. Unger
  • Patent number: 8415393
    Abstract: The present invention provides methods for the design and identification of novel antimicrobial compounds, and provides antimicrobial compounds identified using these methods. These antimicrobial compounds inhibit the binding of a prokaryotic single-stranded DNA binding protein to a polypeptide that binds to the prokaryotic single-stranded DNA binding protein. In some examples, the prokaryotic single-stranded DNA binding protein is prokaryotic Exonuclease I. In one embodiment, the antimicrobial compound has the structure wherein Y is selected from the group consisting of CH2, O, and NH, R1 is selected from the group consisting of H, F, Cl, Br, and I, R2 is selected from the group consisting of H and CF3, R3 is selected from the group consisting of H and CO2H, R4 is selected from the group consisting of H and OH, and R5 is selected from the group consisting of H, alkoxy, and NO2.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: April 9, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James L. Keck, Douglas A. Bernstein
  • Patent number: 8404752
    Abstract: This invention provides for methods of treating a subject suffering from central nervous system injury, including traumatic brain injury, comprising administering to the subject an amount of a perfluorocarbon. This invention also provides for use of a perfluorocarbon in the manufacture of a medicament for treating a subject suffering from central nervous system injury including traumatic brain injury. This invention further provides for a pharmaceutical composition comprising a perfluorocarbon for use in treating a subject suffering from central nervous system injury, including traumatic brain injury.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: March 26, 2013
    Assignees: Oxygen Biotherapeutics, Inc., Virginia Commonwealth University
    Inventors: M. Ross Bullock, Bruce Spiess, Deborah P. Thompson
  • Publication number: 20130071450
    Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.
    Type: Application
    Filed: November 15, 2012
    Publication date: March 21, 2013
    Applicant: COVIDIEN LP
    Inventor: Covidien LP
  • Patent number: 8337870
    Abstract: An active agent delivery composition is provided that allows topical delivery of active agents including vitamin A and its derivatives. A polyhalogenic vehicle such as methoxyonafluorobutane or ethoxyonafluorobutane serves as a coupler for an active agent and a silicone carrier so as to allow solubilization of active agents not normally miscible in silicones and providing a moisture maintaining composition.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: December 25, 2012
    Assignee: Young Pharmaceuticals, Inc.
    Inventor: John E. Kulesza
  • Publication number: 20120164231
    Abstract: An artificial oxygen carrier (AOC) for use in the body. A first gas permeable first shell encloses an oxygen carrying agent. The first shell has a second oxygen carrying agent surrounding it, and there is a second gas permeable shell enclosing the second agent. The concentric shells are not subject to turbulent breakup, or chemical decomposition, do not release the agents.
    Type: Application
    Filed: August 24, 2010
    Publication date: June 28, 2012
    Inventors: Agnes Ostafin, Hiroshi Mizukami
  • Patent number: 8206728
    Abstract: Disclosed are sunscreen compositions containing at least one sunscreen agent, a volatile solvent comprising a cosmetically acceptable lower alkanol, and a fluorinated alkyl ether, and methods of making and using same.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: June 26, 2012
    Assignee: L'Oréal
    Inventors: Anil Shah, Isabelle Hansenne, Angelike Galdi
  • Publication number: 20120083510
    Abstract: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.
    Type: Application
    Filed: September 30, 2011
    Publication date: April 5, 2012
    Inventor: Gerald Klein
  • Publication number: 20120076777
    Abstract: The present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent delivered in combination with the fluorochemical composition.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 29, 2012
    Applicant: MTM Research LLC
    Inventor: Matthew T. McLeay
  • Publication number: 20110306581
    Abstract: Perfluorocarbon emulsions having a high stability and good oxygen release are disclosed and described. These perfluorocarbon emulsions are typically for use as artificial oxygen carriers. The perfluorocarbon emulsions include a disperse phase of a perfluorocarbon and an emulsion stabilizer, and continuous phase. The emulsion stabilizer can primarily include a poly(ethylene oxide) block copolymer. These stabilized perfluorocarbon emulsions can be used in liquid and/or hydrogel phases of perfusion bioreactors or various other culture systems to enhance cell viability in thick tissue constructs, or as blood substitutes, although other applications may also be considered.
    Type: Application
    Filed: December 8, 2009
    Publication date: December 15, 2011
    Applicant: University of Utah Research Foundation
    Inventors: Natalya Y. Rapoport, Glenn D. Prestwich, Russell Morris Condie
  • Publication number: 20110230566
    Abstract: Disclosed are perfluorocarbon compositions for cosmetic applications, in particular, for application to the periocular skin, and methods for using the same.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 22, 2011
    Inventors: Maria Isabel Tamargo, Aharon Grossman, Richard Kiral
  • Publication number: 20110223243
    Abstract: The invention relates to dispersions of artificial oxygen carriers, wherein the dispersions contain capsules with reversible oxygen storage capacity, the capsules comprising an oxygen-permeable capsule material, that contains and/or encloses fluorinated, particularly perfluorinated hydrocarbons, preferably perfluorocarbons. The dispersions are particularly suitable as a blood substitute, preferably for the purpose of transfusion, e.g. in states of blood loss of the human or animal body, in particular following surgical interventions, accidents, injuries etc, or for the prophylactic treatment and/or treatment by therapy of ischaemic states or states following a reperfusion.
    Type: Application
    Filed: July 8, 2009
    Publication date: September 15, 2011
    Inventors: Herbert De Groot, Christian Mayer, Frank Petrat, Michael Kirsch
  • Publication number: 20110171188
    Abstract: The invention relates to a non-thermal plasma for treatment of a surface, particularly for the treatment of a wound (1), wherein the plasma comprises a partially ionized carrier gas and at least one additive, which preferably has a sterilizing effect on the treated surface and/or improves the healing of the wound (1). Further, the invention relates to a corresponding apparatus and method.
    Type: Application
    Filed: August 17, 2009
    Publication date: July 14, 2011
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V
    Inventors: Gregor Morfill, Bernd Steffes, Tetsuji Shimizu, Rene Pompl, Tetiana Nosenko, Wilhelm Stolz, Georg Isbary, Hans-Ulrich Schmidt
  • Publication number: 20110144216
    Abstract: This invention relates to compositions, methods and systems having utility in numerous applications, and in particular, uses for compositions containing the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure:
    Type: Application
    Filed: December 15, 2010
    Publication date: June 16, 2011
    Applicant: HONEYWELL INTERNATIONAL INC.
    Inventors: Ryan Hulse, Gary John Zyhowski, Bjorn Hofman, Dave Williams, Gary Knopeck, Robert G. Richard, Rajat S. Basu, Rajiv Ratna Singh
  • Publication number: 20110086923
    Abstract: The subject application provides for a method of increasing oxygen level in a sex organ of a subject comprising topically administering to the subject an amount of a perfluorocarbon effective to increase the oxygen level in the sex organ of the subject. The subject application also provides for the use of a perfluorocarbon in the manufacture of a composition for increasing oxygen level in a sex organ of a subject. The subject application also provides for a composition comprising a perfluorocarbon for use in increasing oxygen level in a sex organ of a subject.
    Type: Application
    Filed: July 27, 2010
    Publication date: April 14, 2011
    Inventors: Deborah P. Thompson, Richard Kiral, Chris Stern
  • Publication number: 20110044919
    Abstract: The invention is directed to a cosmetic composition comprising at least one perfluorinated component and at least one aromatic component, wherein the aromatic component is present in an amount sufficient to compatibilize the fluorinated component in the cosmetic composition; transfer resistant, long wearing or other types of cosmetic or pharmaceutical compositions containing the components and a method for compatibilizing a fluorinated component in a cosmetic composition using an aromatic component, and cosmetic compositions containing at least one perfluorinated amide.
    Type: Application
    Filed: August 11, 2008
    Publication date: February 24, 2011
    Inventors: Paolo U. Giacomoni, Phillip Cummins, Peter J. Lentini, Manuel L. Tan, John R. Castro, Ismail Ahmed Syed, Garrett William Vanderover
  • Publication number: 20110044903
    Abstract: The present invention provides methods for the preparation of gas-filled microbubbles, and methods of using for therapeutic and/or diagnostic applications. In particular, the methods of the invention allow for the preparation of gas-filled microbubbles having narrow size distributions and defined ultrasonic properties.
    Type: Application
    Filed: March 20, 2009
    Publication date: February 24, 2011
    Applicant: The Board of Trustees of the University of Arkansas
    Inventor: Michael J. Borrelli
  • Patent number: 7887835
    Abstract: A steroid ester compound of a terminally-fluorinated alkyl fatty acid, a steroid compound having bis(trifluoromethyl)phenyl group, a phosphatidylserine compound having a terminally-fluorinated alkyl group, a glyceride compound having bis(trifluoromethyl phenyl group, or a glyceride compound having a terminally-fluorinated alkyl group. A vascular lesion can be selectively imaged by using a contrast medium comprising a liposome containing said compound or a salt thereof.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: February 15, 2011
    Assignee: FUJIFILM Corporation
    Inventors: Kazunobu Takahashi, Kazuhiro Aikawa
  • Publication number: 20110027384
    Abstract: The present invention provides a photosensitising composition comprising a mixture of at least one oxygen carrier, at least one oxidising agent and at least one surfactant, and its uses. The ratio of the at least one oxygen carrier to the at least one oxidising agent to the at least one surfactant may be in the range of 50:40:10 to 80:19.8:0.2. The photosensitising composition may be used for treating and/or preventing conditions caused by microorganisms.
    Type: Application
    Filed: April 6, 2009
    Publication date: February 3, 2011
    Applicant: National University of Singapore
    Inventors: Anil Kishen, Saji George
  • Patent number: 7842730
    Abstract: Medicine, in particular medications for treating blood losses, hypoxic and ishemic states, for improving a blood oxygen supply and for preserving isolated perfused organs and tissues. The inventive medical emulsion of perfluororganic compounds includes rapidly excretable perfluororganic compounds such as perfluordecalin, perfluoractilbromide, a perfluoroganic additive embodied in the form of a mixture of perfluorinated tertiary amines and phospholipids in the form of a water-salt dispersion. The perfluordecalin and perfluoractilbromide are contained in the composition of the rapidly excretable perfluororganic compounds at a ratio ranging from 10:1 to 1:10. The mixture of perfluorinated tertiary amines is embodied in the form of the mixture of perfluorotpripropylamine and the co-products thereof: cis- and trans-isomers perfluor-1-propyl 3,4-dimethylpirrolidone and perfluor-1-propyl-4-methhylpiperidine.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: November 30, 2010
    Inventors: Irina Nikolaievna Kuznetsova, Evgeny Ilich Maievsky
  • Publication number: 20100267842
    Abstract: The subject application provides for an emulsion comprising an amount of a perfluorocarbon liquid dispersed as particles within, a continuous liquid phase, wherein the dispersed particles have a monomodal particle size distribution and uses thereof. The subject application also provides for a method of manufacturing a perfluorocarbon emulsion, a process for preparing a pharmaceutical product containing a PFC emulsion and a process for validating a batch of an emulsion for pharmaceutical use.
    Type: Application
    Filed: April 15, 2010
    Publication date: October 21, 2010
    Inventors: Richard Kiral, Deborah P. Thompson, Gary L. Clauson
  • Patent number: 7767232
    Abstract: Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used, for example, to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: August 3, 2010
    Assignee: New York University
    Inventors: Evgeny Nudler, Ruslan Rafikova, Olga Rafikova
  • Publication number: 20100178347
    Abstract: This invention provides for methods of treating a subject suffering from central nervous system injury, including traumatic brain injury, comprising administering to the subject an amount of a perfluorocarbon. This invention also provides for use of a perfluorocarbon in the manufacture of a medicament for treating a subject suffering from central nervous system injury including traumatic brain injury. This invention further provides for a pharmaceutical composition comprising a perfluorocarbon for use in treating a subject suffering from central nervous system injury, including traumatic brain injury.
    Type: Application
    Filed: July 17, 2009
    Publication date: July 15, 2010
    Inventors: M. Ross Bullock, Bruce Spiess, Deborah P. Thompson
  • Publication number: 20100093873
    Abstract: This invention describes a novel, two-step method for administering PFC. The first step is designed to block the RES by administration of empty, small, liposomal vesicles (ESV) that are rapidly and preferentially engulfed by macrophages, thereby inhibiting their phagocytosis of subsequently infused PFC emulsions. The second step is the subsequent injection of PFC. ESV are devoid of materials that interfere with the macrophage's metabolic processes and do not impair their ability to clear the circulation of pathogenic organisms. Inhibition of the removal of PFC from the blood stream by the RES will achieve increased circulating PFC, enhanced binding and transport of oxygen throughout the blood stream and consequential reduction of undesirable consequences such as organomegaly and cytokine toxicity.
    Type: Application
    Filed: October 1, 2009
    Publication date: April 15, 2010
    Inventor: Sidney L. Goldfischer
  • Patent number: 7618988
    Abstract: Compounds of formula I in which R has a meaning as indicated in claim 1, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: November 17, 2009
    Assignee: Merck Patentgesellschaft
    Inventors: Henning Böttcher, Ralf Devant, Maria Devant, legal representative, Gerd Bartoszyk, Hermann Russ, Frank Weber, Christoph Seyfried
  • Publication number: 20090170811
    Abstract: The present invention relates to a composition for use in the treatment of a detached retina, comprising an oil and an additive capable of increasing the extensional viscosity of the oil. The present invention also relates to a method and kit of parts for producing the composition.
    Type: Application
    Filed: May 18, 2006
    Publication date: July 2, 2009
    Inventors: Michael Joseph Garvey, Rachel Lucinda Williams, Michael Day
  • Publication number: 20090169591
    Abstract: In accordance with one aspect of the invention, implantable and insertable medical articles are provided which are useful for the local treatment of tumors. These medical articles comprise one or more active agents that influence the local tumor environment in vivo, for example, decreasing the level of nutrients in the local tumor environment, inhibiting the utilization of nutrients in the local tumor environment, decreasing the amount of molecular oxygen and/or reactive oxygen species in the local tumor environment, or increasing the amount of molecular oxygen and/or reactive oxygen species in the local tumor environment. Other aspects of the invention pertain to methods of treatment that employ such medical articles. Still other aspects of the invention pertain to methods of making such medical articles.
    Type: Application
    Filed: December 19, 2008
    Publication date: July 2, 2009
    Applicant: BOSTON SCIENTIFIC SCIMED, INC.
    Inventors: Goldi Kaul, John E. O'Gara
  • Publication number: 20080249188
    Abstract: A method for cerebral and systemic cooling by providing a nebulized liquid having a boiling point of 38-300° C. The nebulized liquid is delivered as a mist or a spray via the nasal and/or oral cavities of a patient. The mist causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis. Compositions and medical devices for cerebral and systemic cooling are also provided. Cooling assemblies, and methods of use, are also provided that include flexible balloon assemblies that are inserted to various locations in a patient's body. The flexible balloons are then infused with a liquid having a temperature between about ?20° C. and about 37° C. The flexible balloon assemblies can be inserted into the nasal cavity, oral cavity, throat, stomach, and other locations to effect cerebral cooling.
    Type: Application
    Filed: April 11, 2008
    Publication date: October 9, 2008
    Inventors: Denise Barbut, Allan Rozenberg, John K. Hoffman
  • Publication number: 20080227870
    Abstract: The present invention describes biologically compatible inert perfluorocarbon liquids capable of removing carcinogens from cells and thereby reducing the risk of cancerous cell transformation. This invention can be used to reduce the build-up of carcinogens, and thus be used as prophylactic medicaments in reducing the risk of chemically induced cancerous cell transformation and thus cancer. These liquids can be used as medicaments applied to any organ of the body; such an application would reduce the build-up of carcinogenic chemicals within cells of that organ and as such can be used to reduce the risk of a variety of cancers produced through chemical carcinogenesis. Such cancers include lung cancer, stomach cancer, rectal cancer, and certain types of skin cancer.
    Type: Application
    Filed: December 1, 2005
    Publication date: September 18, 2008
    Inventor: Kaizen Robert Matsumoto
  • Patent number: 7358262
    Abstract: The present invention relate to methods of identifying a genotype-selective agent. In certain embodiments, the invention relates to agents that are selectively toxic to engineered human tumorigenic cells.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: April 15, 2008
    Assignee: Whitehead Institute for Biomedical Research
    Inventor: Brent R. Stockwell
  • Patent number: 7345174
    Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: March 18, 2008
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York
    Inventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas A. Miller, Paul A. Marks, Victoria M. Richon, Richard A. Rifkind
  • Patent number: 7026360
    Abstract: The new pharmaceutical compositions contain, apart from one or more active ingredient(s), between 0.01 and 60% w/w of the compounds of formula I with n and m>18 and <46 and with molecular weights between ˜600 and ˜8000 for the enhancement of absorption of the active ingredient(s). Moreover, such compositions may contain also between 0.01 and 20% w/w of Phosphatidylcholine.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: April 11, 2006
    Assignee: Inpharma S.A.
    Inventor: Norberto Festo
  • Patent number: 6894079
    Abstract: Disclosed are methods for reducing the injury to tissues, cells, microorganisms or lipids caused by free radicals. The method comprises exposing a composition comprising perfluorocarbon to the tissue, cell, microorganism or lipids in need of such a treatment. Perfluorocarbons may be used neat in solutions, as gases or as emulsions.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: May 17, 2005
    Inventors: Alexandre T. Rotta, Bradley P. Fuhrman, Bjorn Gunnersson, David M. Steinhorn, Lynn J. Hernan
  • Patent number: 6878750
    Abstract: This invention describes the new benzocycloheptenes of general formula I in which R1, R2 and SK have the meanings that are indicated in the description. The new compounds have selective estrogenic activity on bones and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: April 12, 2005
    Assignee: Schering AG
    Inventors: Rolf Bohlmann, Jorg Kroll, Hermann Kuenzer, Christa Hegele-Hartung, Monika Lessl, Rosemarie Lichtner, Yukishige Nishino
  • Publication number: 20040176473
    Abstract: The present invention is directed, inter alia, to a method for delivering a compound into a cell comprising administering to the cell the compound to be delivered, an organic halide, and/or a carrier. Ultrasound may also be applied, if desired.
    Type: Application
    Filed: March 18, 2004
    Publication date: September 9, 2004
    Applicant: ImaRx Pharmaceutical Corp.
    Inventors: Evan C. Unger, Thomas McCreery
  • Patent number: 6749869
    Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: June 15, 2004
    Assignee: Ecolab
    Inventors: Francis L. Richter, Cathy M. Paquette, Richard K. Staub
  • Patent number: 6653354
    Abstract: The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: November 25, 2003
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 6653353
    Abstract: Cosmetic or personal care compositions comprise: a hair styling polymer having one or more groups selected from acidic functional groups, anionic groups derived from the acidic functional groups or a mixture of said groups; a partially or fully fluorinated compound having one or more groups selected from amino groups, acid salts of the amino groups or a mixture of said groups, wherein the partially or fully fluorinated compound comprises an aromatic ring; and a cosmetically acceptable diluent or carrier. The compositions are particularly effective under high humidity conditions.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: November 25, 2003
    Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.
    Inventors: Gerald Adams, Ezat Khoshdel
  • Publication number: 20030060421
    Abstract: Provided, among other things, is a kit providing pre-measured amounts of components to form a fluorocarbon nutrient emulsion capable of carrying oxygen to living tissue, the kit comprising: constituent solutions, emulsions or particle compositions, which are the constituent compositions, containing pre-measured amounts of components for making the fluorocarbon nutrient emulsion, the constituent compositions comprising: poly-fluorinated, oxygen-carrying compound; a physiologically acceptable emulsifying agent effective to emulsify the polymer; a nutrient-providing effective amount of carbohydrate; nutrient-providing effective amounts of amino acids or amino acid precursors; an oncotic agent in amount effective to provide, in conjunction with the other components of the solution, a physiologically acceptable oncotic pressure; and sufficient salts and buffering agents to provide a physiological osmotic pressure and physiologically appropriate concentrations of potassium and sodium ions; wherein constituent compo
    Type: Application
    Filed: July 19, 2001
    Publication date: March 27, 2003
    Applicant: Neuron Therapeutics, Inc.
    Inventors: David P. Hesson, Glenn David Frazer, Timothy J. Pelura
  • Patent number: 6528545
    Abstract: Fluorocarbon emulsions comprising a stabilizing, particle size controlling fluorophilic/hydrophilic compound which can have the formula RF1—W—RH1  (I) wherein RF1 is a linear, branched or cyclic C2-14 fluorocarbon group; RH1 is a linear, branched or cyclic C2-18 saturated or unsaturated hydrocarbon group; and W is absent or is a bivalent species chosen from the group consisting of —O—, —S—, or various fluorinated structures. Use of the fluorophilic/lipophilic compound in the dispersions of the invention provides stable particle size and efficient emulsification. The dispersions of the invention can comprise biologically useful additive and can be used for various purposes, as oxygen carriers, contrast agents, or diagnostic agents.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: March 4, 2003
    Inventors: Jean G. Riess, Michele Postel, Luis Sole-Violan, Marie-Pierre Krafft, Chantal Cornelus